Head-To-Head Survey: ABIVAX Société Anonyme (NASDAQ:ABVX) & SIGA Technologies (NASDAQ:SIGA)

ABIVAX Société Anonyme (NASDAQ:ABVX) and SIGA Technologies (NASDAQ:SIGA) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, valuation, risk, dividends and analyst recommendations.

Risk & Volatility

ABIVAX Société Anonyme has a beta of -0.2, meaning that its stock price is 120% less volatile than the S&P 500. Comparatively, SIGA Technologies has a beta of 0.98, meaning that its stock price is 2% less volatile than the S&P 500.

Profitability

This table compares ABIVAX Société Anonyme and SIGA Technologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ABIVAX Société Anonyme	N/A	N/A	N/A
SIGA Technologies	49.33%	49.06%	38.72%

Earnings and Valuation

This table compares ABIVAX Société Anonyme and SIGA Technologies”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ABIVAX Société Anonyme	N/A	N/A	-$159.90 million	N/A	N/A
SIGA Technologies	$138.72 million	2.90	$68.07 million	$0.82	6.88

SIGA Technologies has higher revenue and earnings than ABIVAX Société Anonyme.

Insider & Institutional Ownership

47.9% of ABIVAX Société Anonyme shares are owned by institutional investors. Comparatively, 55.4% of SIGA Technologies shares are owned by institutional investors. 1.5% of SIGA Technologies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for ABIVAX Société Anonyme and SIGA Technologies, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ABIVAX Société Anonyme	0	1	5	1	3.00
SIGA Technologies	0	0	0	0	0.00

ABIVAX Société Anonyme presently has a consensus target price of $38.00, indicating a potential upside of 438.24%. Given ABIVAX Société Anonyme’s stronger consensus rating and higher possible upside, equities analysts plainly believe ABIVAX Société Anonyme is more favorable than SIGA Technologies.

Summary

SIGA Technologies beats ABIVAX Société Anonyme on 8 of the 12 factors compared between the two stocks.

About ABIVAX Société Anonyme

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.

About SIGA Technologies

SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.